Zihang Zhou

Zihang Zhou

Auto-generated profile, based on publicly available information

Zihang Zhou

Department of Neurobiology, Xuzhou Medical University, 221004 Xuzhou, Jiangsu, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2023 in Neural Regeneration Research
Verified
Journal Article
Open access
ZZZihang Zhou
Zihang Zhou
YYYalong Yan
Yalong Yan
HGHeng Gu
Heng Gu
RSRuiao Sun
Ruiao Sun
ZLZihan Liao
Zihan Liao
CTCHUANXI TANG
CHUANXI TANG
Parkinson's disease can affect not only motor functions but also cognitive abilities, leading to cognitive impairment. One common issue in Parkinson's disease with cognitive dysfunction is the difficulty in executive functioning. Executive functions help us plan, organize, and control our actions based on our goals. The brain area responsible for executive functions is called the prefrontal cortex. It acts as the command center for the brain, especially when it comes to regulating executive functions. The role of the prefrontal cortex in cognitive processes is influenced by a chemical messenger called dopamine. However, little is known about how dopamine affects the cognitive functions of patients with Parkinson's disease. In this article, the authors review the latest research on this topic. They start by looking at how the dopaminergic system, is altered in Parkinson's disease with executive dysfunction. Then, they explore how these changes in dopamine impact the synaptic structure, electrical activity, and connection components of the prefrontal cortex. The authors also summarize the relationship between Parkinson's disease and dopamine-related cognitive issues. This information may offer valuable insights and directions for further research and improvement in the clinical treatment of cognitive impairment in Parkinson's disease.

16 September 2026 in Journal of Integrative Neuroscience
Verified
Journal Article
Open access
PDF file
RCRui Chen
Rui Chen
PXPeng Xie
Peng Xie
XFXinrui Fan
Xinrui Fan
ZZZihang Zhou
Zihang Zhou
CMChunyan Mu
Chunyan Mu
QJQiuhong Ji
Qiuhong Ji
Background: Fluorosis can induce cognitive dysfunction. The cognitive impairment caused by fluorosis is closely related to endoplasmic reticulum stress (ERS) and abnormal lysosomal acidification. However, the specific molecular mechanism is not known, and effective intervention strategies are lacking. Diterpene ginkgolides meglumine injection (DGMI) is used clinically as a neuroprotective agent, but whether it can inhibit ERS, regulate lysosomal acidification, and ameliorate fluorosis-induced cognitive dysfunction merits investigation. Methods: We used the Morris water maze to detect the cognitive function of mice, evaluated the neuronal survival by Nissl staining, assessed the apoptotic status in hippocampal neurons of mice by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining, and observed the degree of synaptic plasticity damage using Golgi staining and transmission electron microscopy. In cell experiments, we used the OG488 acidophilic fluorescent probe to detect lysosomal acidity; detected the co-localization of HSP90B1 with the ER and the co-localization of the chloride channel, voltage-sensitive 7 (ClC-7) with lysosomes using immunofluorescence technology; employed co-immunoprecipitation to detect the binding of HSP90B1, ClC-7, and membrane-associated RING-CH protein 1 (MARCHF1) as well as the ubiquitination degradation level of ClC-7; used western blotting to measure expression of ERS-related proteins (PERK, IRE1α, ATF6), glycogen synthase kinase 3β, and mammalian target of rapamycin signals. Results: DGMI significantly improved cognitive dysfunction in C57BL/6 mice with fluorosis, inhibited hippocampal neuronal apoptosis, and improved synaptic plasticity damage. In cell experiments, the detection results of apoptosis and percent survival were consistent with those of animal experiments in that DGMI could alleviate sodium fluoride-induced ERS and lysosomal-acidification disorders in HT22 cells. DGMI downregulates the expression of the ER chaperone HSP90B1, weakens its interaction with ClC-7, thereby inhibiting the MARCHF1 E3 ligase-mediated ubiquitination and degradation of ClC-7, ultimately alleviating lysosomal acidification disorders and improving cognitive function. Conclusions: DGMI may exert cognitive protective effects against fluorosis-induced cognitive impairment by regulating lysosomal acidification through the HSP90B1–ClC-7 axis, which also alleviates ERS, apoptosis, and other related neuropathologic injuries.